US Cancer Nuclear Medicine Diagnostics Market Trends 2031
US Cancer Nuclear Medicine Diagnostics Market Trends 2031
Segments - US Prostate Cancer Nuclear Medicine Diagnostics Market by Types (Single-photon Emission Computerized Tomography and Positron Emission Tomography) and Products (Fluorine-18, Carbon-11, and Ga 68 PSMA) – Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-1443
| 4.7 Rating
| 73 Reviews
| 213 Pages
| Format :
Report Description
The US prostate cancer nuclear medicine diagnostics market size was USD 258.60 Million in 2022 and is likely to reach USD 645.59 Million by 2031, expanding at a CAGR of 10.7% during 2023–2031. The growth of the market is attributed to the increasing prevalence of prostate cancer and accurate diagnosis of the diseases.
When cells in the body begin to grow out of control, cancer develops. Cancer cells can develop in almost any organ of the body and spread to other parts of the body. Prostate cancer refers to a kind of cancer that affects the male reproductive system.
Prostate cancer is usually slow-growing and stable, though it can occasionally migrate from the prostate (gland) to other parts of the body, such as the bone and lymph node. Prostate cancer has no symptoms at first, but in extreme cases, it can cause pain when urinating and problems during sexual intercourse.
Nuclear medicine is a type of imaging that employs radioactive elements to diagnose and treat prostate cancer. It is a type of diagnostic imaging that aids radiologists in determining the cancer stage. If necessary, it can also be used as a therapy to promote survival, reduce discomfort, and enhance overall quality of life. Finally, if the patient requires therapy, nuclear medicine may be utilized to monitor the cancer's progress.
Radiotracer is a safe, small amount of radioactive element that is injected into your bloodstream, inhaled as a gas, or consumed orally. The radiotracer moves through the body, emitting gamma rays, and is taken up by various regions of the body, depending on the tissue's "affinity," or what sections of the body it is naturally drawn to.
Market Trends, Drivers, Restraints, and Opportunities
-
Increasing prevalence of prostate cancer and the growth of innovative radiopharmaceuticals are projected to drive the market growth during the forecast period.
-
Rising demand for preventive and accurate diagnosis of the diseases are projected to boost the market growth the forecast period.
-
Increasing adoption of Positron Emission Tomography (PET) imaging of prostate cancer because of its higher accuracy compared to other diagnostic methods is estimated to propel the market growth during the forecast period.
-
Favorable reimbursement policies and programs such as Medicaid, Medicare, and the Health Insurance programs in the US are expected to boost the market growth in the coming years.
-
High cost of test is anticipated to impede the market growth during the forecast period.
- Increased emphasis on R&D for development of innovative imaging agents is expected to offer lucrative opportunities for the market players.
Scope of US Prostate Cancer Nuclear Medicine Diagnostics Market Report
The report on the US prostate cancer nuclear medicine diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
US Prostate Cancer Nuclear Medicine Diagnostics Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Types (Single-photon Emission Computerized Tomography and Positron Emission Tomography) and Products (Fluorine-18, Carbon-11, and Ga 68 PSMA) |
|
Country Scope |
US |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Blue Earth Diagnostics, Inc.; PETNET Solutions, Inc.; Cardinal Health; Lantheus Medical Imaging; Jubilant Pharma Ltd. (Triad Isotopes, Inc.); NCM-USA LLC; Progenics Pharmaceuticals, Inc.; Telix Pharmaceuticals, Inc.; ImaginAb, Inc.; Theragnostics Ltd.; Novartis AG; and Alliance Medical Group |
US Prostate Cancer Nuclear Medicine Diagnostics Market Segment Insights
Positron emission tomography segment is expected to account for a key share
Based on types, the US prostate cancer nuclear medicine diagnostics market is bifurcated into single-photon emission computed tomography (SPECT) and positron emission tomography (PET). The positron emission tomography segment is expected to account for a key share of the market during the forecast period due to its better image quality and higher reimbursement for its treatments than standard SPECT nuclear medicine diagnostic treatments.
Gallium-68, Fluorine-18, Zirconium-89, Copper-64, and Carbon-11 are radioisotopes used in PET prostate cancer diagnostics. F-18 FDG, Fluciclovine F 18, 18F-NaF, and C-11 have been approved by the US Food and Drug Administration for use in PET imaging for prostate cancer diagnosis, while other PET tracers are still in clinical trials.
On the other hand, the single-photon emission computed tomography segment is anticipated to expand at a rapid pace during the forecast period due to the low cost of scans and the ability to employ commonly obtainable radioisotopes with a longer life than PET.
Furthermore, the US market is expected to grow due to an increase in clinical research on SPECT radiopharmaceuticals to enable early detection of prostate cancer. For example, the first anti-PSMA tracer discovered to be beneficial for SPECT imaging was capromab pendetide labeled with Indium-111.
GA 68 PSMA segment is expected to constitute a large share
Based on products, the US prostate cancer nuclear medicine diagnostics market is segmented into Fluorine-18, Carbon-11, and GA 68 PSMA. The GA 68 PSMA segment is expected to constitute for a key share of the market during the forecast period due its higher accuracy and sensitivity. Prostate-specific Membrane Antigen (PSMA) expression is 100-1,000 times higher in prostate cancer, and the number grows as the tumor stage progresses.
New PSMA-targeting drugs are now in clinical trials and are projected to enter the market throughout the forecast period. In Phase III clinical studies, two distinct PSMA-PET imaging agents, 68Ga-PSMA-11 and 18F-DCFPyL, have been tested. By merging PET with MRI and CT, new technologies are being developed, and radioisotopes that are compatible with such integrated technology are being researched.
On the other hand, the Fluorine-18 segment is anticipated to expand at a rapid pace during the forecast period owing to its efficient bio-distribution and relatively low urinary excretion. Fluorine-18 flucicovine and Fludeoxyglucose F 18 (F-18 FDG) are certified radioisotopes, whereas F 18 sodium fluoride (18F-NaF) and 18F-Choline are PET tracers that have been extensively explored for their potential to identify cancers, including prostate cancer.
US market is anticipated to expand at an impressive CAGR
The US prostate cancer nuclear medicine diagnostics market is anticipated to expand at an impressive CAGR during the forecast period owing to increasing prevalence of the prostate cancer, changing lifestyle and favorable reimbursement policies. The presence of key global players and favorable regulatory policies in the country are major factors expected to accelerate the development of cancer therapies.
Several programs in the country such as[A1] Medicaid, Medicare, and the Health Insurance programs, are expected to provide growth prospects for market players. The Centers for Medicare & Medicaid Services (CMS), for example, covers PET services under the National Coverage Determination (NCD), which includes tracers required for prostate cancer diagnosis.
Presence of several major companies in the country which are developing novel diagnostic agents in order to improve diagnosis and provide patients with a more accurate imaging technique. All these factors are likely to boost the market growth during the forecast period.
Segments
The US prostate cancer nuclear medicine diagnostics market has been segmented on the basis of
Types
- Single-photon Emission Computerized Tomography
- Positron Emission Tomography
Products
- Fluorine-18
- Carbon-11
- Ga 68 PSMA
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Blue Earth Diagnostics, Inc.
- PETNET Solutions, Inc.
- Cardinal Health
- Lantheus Medical Imaging
- Jubilant Pharma Ltd. (Triad Isotopes, Inc.)
- NCM-USA LLC
- Progenics Pharmaceuticals, Inc.
- Telix Pharmaceuticals, Inc.
- ImaginAb, Inc.
- Theragnostics Ltd.
- Novartis AG
- Alliance Medical Group
Competitive Landscape
Key players competing in the US prostate cancer nuclear medicine diagnostics market are Blue Earth Diagnostics, Inc.; PETNET Solutions, Inc.; Cardinal Health; Lantheus Medical Imaging; Jubilant Pharma Ltd. (Triad Isotopes, Inc.); NCM-USA LLC; Progenics Pharmaceuticals, Inc.; Telix Pharmaceuticals, Inc.; ImaginAb, Inc.; Theragnostics Ltd.; Novartis AG; and Alliance Medical Group.
Some of the key business strategies employed by the companies in the market are mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For example, in February 2018, Cancer Targeted Technology Company granted Advanced Accelerator Applications a license to continue developing and commercializing CTT1057.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Cancer Nuclear Medicine Diagnostics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Cancer Nuclear Medicine Diagnostics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Cancer Nuclear Medicine Diagnostics Market - Supply Chain
4.5. Global Cancer Nuclear Medicine Diagnostics Market Forecast
4.5.1. Cancer Nuclear Medicine Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Cancer Nuclear Medicine Diagnostics Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Cancer Nuclear Medicine Diagnostics Market Absolute $ Opportunity
5. Global Cancer Nuclear Medicine Diagnostics Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Cancer Nuclear Medicine Diagnostics Market Size and Volume Forecast by Types
5.3.1. Single-photon Emission Computerized Tomography
5.3.2. Positron Emission Tomography
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Cancer Nuclear Medicine Diagnostics Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Cancer Nuclear Medicine Diagnostics Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Cancer Nuclear Medicine Diagnostics Demand Share Forecast, 2019-2026
7. North America Cancer Nuclear Medicine Diagnostics Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Cancer Nuclear Medicine Diagnostics Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Cancer Nuclear Medicine Diagnostics Market Size and Volume Forecast by Types
7.4.1. Single-photon Emission Computerized Tomography
7.4.2. Positron Emission Tomography
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Cancer Nuclear Medicine Diagnostics Demand Share Forecast, 2019-2026
8. Latin America Cancer Nuclear Medicine Diagnostics Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Cancer Nuclear Medicine Diagnostics Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Cancer Nuclear Medicine Diagnostics Market Size and Volume Forecast by Types
8.4.1. Single-photon Emission Computerized Tomography
8.4.2. Positron Emission Tomography
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Cancer Nuclear Medicine Diagnostics Demand Share Forecast, 2019-2026
9. Europe Cancer Nuclear Medicine Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Cancer Nuclear Medicine Diagnostics Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Cancer Nuclear Medicine Diagnostics Market Size and Volume Forecast by Types
9.4.1. Single-photon Emission Computerized Tomography
9.4.2. Positron Emission Tomography
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Cancer Nuclear Medicine Diagnostics Demand Share Forecast, 2019-2026
10. Asia Pacific Cancer Nuclear Medicine Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Cancer Nuclear Medicine Diagnostics Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Cancer Nuclear Medicine Diagnostics Market Size and Volume Forecast by Types
10.4.1. Single-photon Emission Computerized Tomography
10.4.2. Positron Emission Tomography
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Cancer Nuclear Medicine Diagnostics Demand Share Forecast, 2019-2026
11. Middle East & Africa Cancer Nuclear Medicine Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Cancer Nuclear Medicine Diagnostics Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Cancer Nuclear Medicine Diagnostics Market Size and Volume Forecast by Types
11.4.1. Single-photon Emission Computerized Tomography
11.4.2. Positron Emission Tomography
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Cancer Nuclear Medicine Diagnostics Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Cancer Nuclear Medicine Diagnostics Market: Market Share Analysis
12.2. Cancer Nuclear Medicine Diagnostics Distributors and Customers
12.3. Cancer Nuclear Medicine Diagnostics Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Blue Earth Diagnostics, Inc.
12.4.2. PETNET Solutions, Inc.
12.4.3. Cardinal Health
12.4.4. Lantheus Medical Imaging
12.4.5. Jubilant Pharma Ltd. (Triad Isotopes, Inc.)
12.4.6. NCM-USA LLC
12.4.7. Progenics Pharmaceuticals, Inc.
12.4.8. Telix Pharmaceuticals, Inc.
12.4.9. ImaginAb, Inc.
12.4.10. Theragnostics Ltd.
12.4.11. Novartis AG
12.4.12. Alliance Medical Group
Methodology
Related Reports
Some other reports from this category!
Our Clients
